Eventide Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Eventide Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-45,500	Closed	-$13.2M	–	150
2020 Q2	$13.2M	Hold	45,500	–	–	0.29%	87
2020 Q1	$10.8M	Buy	+45,500	New	+$10.4M	0.35%	81
2019 Q2	–	Sell	-26,000	Closed	-$4.78M	–	128
2019 Q1	$4.78M	Sell	26,000 -197,000	-88%	-$36.4M	0.16%	92
2018 Q4	$37M	Sell	223,000 -90,000	-29%	-$15.6M	1.64%	18
2018 Q3	$60.3M	Buy	313,000 +70,000	+29%	+$12.5M	2.22%	7
2018 Q2	$41.3M	Hold	243,000	–	–	1.71%	15
2018 Q1	$39.6M	Buy	243,000 +63,000	+35%	+$10.3M	1.85%	14
2017 Q4	$27M	Hold	180,000	–	–	1.41%	30
2017 Q3	$27.4M	Buy	180,000 +145,400	+420%	+$21.9M	1.55%	25
2017 Q2	$4.46M	Hold	34,600	–	–	0.28%	73
2017 Q1	$3.78M	Hold	34,600	–	–	0.25%	81
2016 Q4	$2.55M	Hold	34,600	–	–	0.17%	91
2016 Q3	$3.02M	Hold	34,600	–	–	0.18%	85
2016 Q2	$2.98M	Hold	34,600	–	–	0.18%	85
2016 Q1	$2.75M	Hold	34,600	–	–	0.15%	94
2015 Q4	$4.35M	Buy	+34,600	New	+$4.18M	0.22%	92

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Eventide Asset Management's VRTX Position: Q3 2020 in Review

Eventide Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2020, closing a stake of 45,500 shares — an estimated $13.2M sold.

Eventide Asset Management first reported a position in VRTX in Q4 2015 and held it in 16 quarters. The position peaked at $60.3M in Q3 2018. 951 funds tracked by Wall St. Rank hold VRTX as of Q3 2020.

Eventide Asset Management reported no remaining Vertex Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Eventide Asset Management sold 45,500 Vertex Pharmaceuticals shares in Q3 2020, an estimated $13.2M.
Eventide Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2015 and held it in 16 quarters.
Eventide Asset Management's Vertex Pharmaceuticals position peaked at $60.3M in Q3 2018.
951 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2020.

Based on Eventide Asset Management's 13F filing for Q3 2020, filed 13 Nov 2020.